Mar Fabregas – General Manager, STADA Spain

STADA’s general manager for Spain, Mar Fabregas, reveals how the acquisition of parts of GSK and Sanofi’s portfolio is helping the global generics company better compete in consumer health. In addition, she analyses the biosimilars market in Spain, where the company recently launched Bevacizumab, and comments on the importance of a diversified presence in the retail and hospital segments.  
I hope that the COVID-19 pandemic has foregrounded the value that [the generics] industry can bring
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report